New study maps rare brain tumors in argentina
NCT ID NCT07631338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at low-grade gliomas, a slow-growing type of brain tumor, in Argentina. Researchers will review medical records from about 40 patients to find out how common these tumors are and how long people live after diagnosis. The goal is to better understand these tumors in middle-income countries and guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult (≥18 years) Hospital Italiano Health Plan affiliates (Cohort 1) and histologically confirmed WHO grade I-II low-grade glioma patients treated at participating centers (Cohort 2), retrospectively identified for incidence and survival analyses.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Study population cohort 1 * Inclusion Criteria * Adult patients (≥18 years old) affiliated to the health plan of Hospital Italiano de Buenos Aires. * Documented clinical follow-up of at least 1 year during the study period. * Exclusion Criteria * Patients not affiliated to the health plan of the Hospital Italiano de Buenos Aires. Study population cohort 2 * Inclusion Criteria * Adult patients (≥18 years) with histopathologically confirmed diagnosis of low-grade glioma (WHO grades I and II). * Exclusion Criteria * Incomplete or doubtful diagnosis based on histopathologic and molecular criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Low-grade glioma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Alemán
RECRUITINGBuenos Aires, Buenos Aires F.D., C1118AAT, Argentina
-
Hospital Italiano de Buenos Aires
RECRUITINGBuenos Aires, Buenos Aires F.D., C1199ABB, Argentina
-
Hospital Italiano sede San Justo Agustín Rocca
RECRUITINGBuenos Aires, San Justo, C1198AAW, Argentina
-
Hospital Privado Universitario de Córdoba
RECRUITINGCórdoba, Córdoba Province, X5016KEH, Argentina
-
Hospital Universitario Austral
RECRUITINGBuenos Aires, Pilar, B1629AHJ, Argentina
-
Hospital de Alta Complejidad El Cruce - Dr. Néstor Kirchner
RECRUITINGBuenos Aires, Florencio Varela, B1888, Argentina
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could dropping one chemo drug improve life for young brain tumor patients?
- Brain surgery safety: live signal monitoring may shield speech, movement, and sight
- Could a parasite drug fight childhood brain tumors?
- A new PET scan tracks brain tumors by their appetite for tryptophan
- Can a simple dye help surgeons see brain tumors in real time?
- Digital tests may offer a new way to track brain health in tumor patients